Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $12,874 | $9,111 | $6,957 | $28,935 |
Gross Profit | 12,874 | 9,111 | 4,358 | 26,423 |
EBITDA | -133,881 | -142,162 | -136,444 | -111,491 |
EBIT | -136,447 | -144,770 | -139,043 | -114,003 |
Net Income | -128,898 | -135,712 | -146,975 | -107,436 |
Net Change In Cash | 12,874 | 9,111 | 6,957 | 28,935 |
Free Cash Flow | -86,176 | -86,116 | -59,198 | -123,168 |
Cash | 189,182 | 120,495 | 130,848 | 171,979 |
Basic Shares | 102,029 | 101,002 | 96,975 | 95,502 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $57,877 | $36,275 | $52,121 | $33,053 |
Gross Profit | 57,877 | 27,299 | 44,549 | 33,053 |
EBITDA | -523,978 | -506,315 | -450,592 | -260,959 |
EBIT | -534,263 | -515,291 | -458,164 | -267,850 |
Net Income | -519,021 | -481,192 | -490,208 | -259,718 |
Net Change In Cash | 57,877 | 36,275 | 52,121 | 33,053 |
Cost of Revenue | 409,977 | -39,120 | ||
Free Cash Flow | -408,071 | -408,071 | -391,677 | -237,786 |
Cash | 189,182 | 226,748 | 523,506 | 123,406 |
Basic Shares | 98,849 | 88,770 | 76,972 | 70,894 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$1.27 |
2024-09-30 | -$1.34 |
2024-06-30 | -$1.52 |
2024-03-31 | -$1.12 |
